Abstract
Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis. The World Health Organization publishes global tuberculosis reports annually in order to provide the latest information in the surveillance of drug resistance. Given the alarming rise of resistance to antitubercular drugs worldwide, finding new cellular targets and developing new analogues or new compounds with greater potency against already known targets are both important aspects in fighting drug-sensitive and drug-resistant M. tuberculosis strains. In this context, the introduction of the phenotypic screens as an efficient tool for the identification of active compounds for tuberculosis drug discovery has improved the possibility to find new effective targets.
With this review we describe the state of art of the currently well validated antitubercular drug targets as well as the advances in discovery of new ones. The main targets will be discussed starting from the oldest such as the enoyl reductase InhA which is constantly repurposed with new inhibitors, through the well assessed targets like the gyrase, the ATP synthetase or the RNA polymerase, up to the hot promiscuous targets decaprenylphosphoryl-Dribose oxidase DprE1 and the mycolic acid transporter MmpL3, or the newly validated and promising targets like the CTP synthetase.
Keywords: Tuberculosis, antitubercular drugs, repurposed targets, promiscuous targets, phenotypic screening, drug design.
Current Medicinal Chemistry
Title:New and Old Hot Drug Targets in Tuberculosis
Volume: 23 Issue: 33
Author(s): Laurent Roberto Chiarelli, Giorgia Mori, Marta Esposito, Beatrice Silvia Orena and Maria Rosalia Pasca
Affiliation:
Keywords: Tuberculosis, antitubercular drugs, repurposed targets, promiscuous targets, phenotypic screening, drug design.
Abstract: Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis. The World Health Organization publishes global tuberculosis reports annually in order to provide the latest information in the surveillance of drug resistance. Given the alarming rise of resistance to antitubercular drugs worldwide, finding new cellular targets and developing new analogues or new compounds with greater potency against already known targets are both important aspects in fighting drug-sensitive and drug-resistant M. tuberculosis strains. In this context, the introduction of the phenotypic screens as an efficient tool for the identification of active compounds for tuberculosis drug discovery has improved the possibility to find new effective targets.
With this review we describe the state of art of the currently well validated antitubercular drug targets as well as the advances in discovery of new ones. The main targets will be discussed starting from the oldest such as the enoyl reductase InhA which is constantly repurposed with new inhibitors, through the well assessed targets like the gyrase, the ATP synthetase or the RNA polymerase, up to the hot promiscuous targets decaprenylphosphoryl-Dribose oxidase DprE1 and the mycolic acid transporter MmpL3, or the newly validated and promising targets like the CTP synthetase.
Export Options
About this article
Cite this article as:
Chiarelli Roberto Laurent, Mori Giorgia, Esposito Marta, Orena Silvia Beatrice and Pasca Rosalia Maria, New and Old Hot Drug Targets in Tuberculosis, Current Medicinal Chemistry 2016; 23 (33) . https://dx.doi.org/10.2174/1389557516666160831164925
DOI https://dx.doi.org/10.2174/1389557516666160831164925 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Phenothiazine: A Better Scaffold against Tuberculosis
Mini-Reviews in Medicinal Chemistry Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Recent Advances in Microwave-Assisted Synthesis and Functionalization of 1,2,3- and 1,2,4-triazoles
Current Organic Chemistry Toll-Like Receptors in Human Infectious Diseases
Current Pharmaceutical Design Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews Cytochrome <i>bc1-aa3</i> Oxidase Supercomplex As Emerging and Potential Drug Target Against Tuberculosis
Current Molecular Pharmacology Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science Microwave Assisted Preparation of New Dicoumarinyl Pyrazoline Derivatives as Antimicrobials
Current Microwave Chemistry The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or Selective Inhibitors?
Mini-Reviews in Medicinal Chemistry Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Bacterial Lipoprotein Biosynthetic Pathway as a Potential Target for Structure-based Design of Antibacterial Agents
Current Medicinal Chemistry Experimental and Clinical Studies on Rifacinna® - The New Effective Antituberculous Drug (Review)
Recent Patents on Anti-Infective Drug Discovery